Maysiglu

Sitagliptin, the active ingredient in Maysiglu, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It belongs to the oral hypoglycemic therapeutic class and is prescribed to improve glycemic control in adults with type 2 diabetes mellitus, especially when blood glucose remains inadequately controlled by diet and exercise alone.

GNH USA supplies Maysiglu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Maysiglu (sitagliptin) is used in the management of type 2 diabetes, a chronic metabolic disorder characterized by insulin resistance. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Combination with metformin: provides additional glycemic reduction when used together. - Adjunct to diet and exercise: serves as an oral therapy for patients whose glucose remains uncontrolled by lifestyle measures alone.

Common Side Effects: - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate head discomfort. - Gastrointestinal upset: includes nausea, abdominal pain or dyspepsia. - Dizziness: occasional light‑headed sensation. - Upper respiratory infection: mild cough or sore throat.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: including rash, angioedema or anaphylaxis. - Hepatic injury: elevated liver enzymes or hepatitis. - Joint pain: unexplained arthralgia that may be disabling. - Bullous skin disorders: rare blistering skin conditions.

Before initiating therapy, consider the following precautions: - Renal function: assess creatinine clearance and adjust dose if needed. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Concomitant insulin or sulfonylureas: monitor for hypoglycaemia. - Elderly patients: start with lower dose and observe tolerance. - Pregnancy and lactation: use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Sitagliptin may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia. - Rifampin: may reduce sitagliptin effectiveness. Moderate Interactions (Monitor Closely): - Diuretics: monitor renal function and electrolytes. - ACE inhibitors: watch for blood pressure changes. - Warfarin: periodic INR checks are recommended.